Markers of efficacy of Infliximab in psoriasis patients



Cite item

Full Text

Abstract

The article presents the results of molecular and genetic studies aimed at determination of molecular markers for forecasting
the clinical response of psoriasis patients to treatment with Infliximab. The authors revealed that it is possible to forecast
high efficacy of treatment with Infliximab in case TT genotype is revealed at the 676 locus of exon 6 of the TNF-RII gene and
IL-10 is present in the blood serum prior to the onset of treatment in the amount of more than 2.7 pg/ml.

References

  1. Гинтер Е.А. Эволюция представлений о генетической природе мультифакториальных заболеваний. Медицинская генетика, 2003; 2: 4: 146-156.
  2. Скрипкин Ю.К., Мордовцев В.Н. Кожные и венерические болезни: руководство для врачей. М.: Медицина, 1999: 116-118.
  3. Campalani E, Barker J. The clinical genetics of psoriasis. Current Genomics 2005; 6: 51-60.
  4. Mease P. TNF-alpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 2004 (Jul); 63 (7): 755-758.
  5. Zhang M, Tracey KJ. Tumor necrоsis factor. In: Thompson A.W. (ed.) The cytokine handbook, 3rd ed. New York: Academic press, 1998: 515-548.
  6. Cordiali-Fei P, Trento E, D.'Agosto G et al. Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in sera and skin lesions. Ann N Y Sci. 2007 (Sep): 1110: 578-589.
  7. Saraceno R, Schipani C, Mazzota A et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008 (Apr); 57; 4: 290-295.
  8. Cordoro KM, Feldman SR. TNF-a Inhibitors in Dermatology. Skin Therapy Lett. 2007 (Sep); 12 (7): 4-6.
  9. Nash PT, Florin THJ Tumour necrosis factor inhibitors. MJA 2005; 183 (4): 205-208.
  10. Nikas SN, Voulgari PV, Takalou IP et al. Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment. Ann Rheum Dis 2005 (Nov); 64 (11): 1665-1667.
  11. A Clemmensen, M Spon, L Skov, et al. Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2011 (Sep); 25 (9): 1037-40.
  12. Evans WE, McLeod HL. Pharmacogenomics - Drug Disposition, Drug Targets, and Side Effects. NEJM 2003 (Feb); 6: 538-549.
  13. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998; 8: 283-289.
  14. Baran W, Szepietowski JC, Mazur G. et al. IL-6 and IL-10 promoter gene polymorphisms in psoriasis vulgaris. Acta Derm Venereol 2008; 88: 2: 113-116.
  15. Heidenreich R, Röcken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol 2009; 90: 3: 232-48.
  16. Rashmi R., Rao KSJ, Basavaraj KH. A comprehensive review of biomarkers in psoriasis. Clin Exp Dermatol 2009; 34: 658-663.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Kubanova A.A., Znamenskaya L.F., Frigo N.V., Volkov I.A., Rotanov S.V., Rezaykina A.V., KUBANOVA A.A., ZNAMENSKAYA L.F., FRIGO N.V., VOLKOV I.A., ROTANOV S.V., REZAIKINA A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies